Advertisement

Topics

Intersect ENT Announces FDA Approval of Newest Steroid Releasing Implant, PROPEL® Contour, for Use in Treating the Frontal and Maxillary Sinuses

08:00 EST 24 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Approval Broadens Patient Population for Localized Drug Delivery Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that the company...

Other Sources for this Article

Intersect ENT, Inc.
Investors:
Jeri Hilleman, 650-641-2105
ir@intersectENT.com
or
Media:
Nicole Osmer, 650-454-0504
nicole@healthandcommerce.com

NEXT ARTICLE

More From BioPortfolio on "Intersect ENT Announces FDA Approval of Newest Steroid Releasing Implant, PROPEL® Contour, for Use in Treating the Frontal and Maxillary Sinuses"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...